SIC
VNDA icon

SJS Investment Consulting’s Vanda Pharmaceuticals VNDA Stock Holding History

SJS Investment Consulting’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.28K Buy
372
+220
+145% +$1.44K ﹤0.01% 1725
2026
Q1 		$1.05K Buy
152
+131
+624% +$1.01K ﹤0.01% 1450
2025
Q4 		$186 Buy
+21
New +$116 ﹤0.01% 1830

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SJS Investment Consulting's VNDA Position: Q2 2026 in Review

SJS Investment Consulting increased its Vanda Pharmaceuticals (VNDA) stake by 145% in Q2 2026, buying an estimated $1.44K and bringing the position to 372 shares worth $2.28K. The position accounts for ﹤0.01% of the portfolio, ranked #1725.

SJS Investment Consulting first reported a position in VNDA in Q4 2025 and has held it in 3 quarters since. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • SJS Investment Consulting held 372 shares of Vanda Pharmaceuticals worth $2.28K as of Q2 2026.
  • SJS Investment Consulting bought 220 Vanda Pharmaceuticals shares in Q2 2026, an estimated $1.44K.
  • Vanda Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1725 holding.
  • SJS Investment Consulting first reported a position in Vanda Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.